Ranolazine (Ranexa®) is indicated for the treatment of chronic angina. Ranolazine (Ranexa®) can be used with beta-blockers, nitrates, calcium channel blockers, antiplatelet therapy, lipid-lowering therapy, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin-receptor blockers.

The use of ranolazine (Ranexa®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Ranolazine (Ranexa®) is a partial fatty-acid oxidation inhibitor that produces anti-ischemic effects without significantly affecting heart rate or blood pressure, although the exact mechanism of action is not known.

Ranolazine (Ranexa®) is approved when all of the following inclusion criteria are met:

- Documentation of a diagnosis of chronic angina
- Documentation of trial and failure with at least one medication from any of the following drugs:
  - Long-acting nitrates: Isosorbide dinitrate, Isosorbide mononitrate, Nitroglycerin patches
  - Beta-blockers: Atenolol, Acebutolol, Carvedilol, Penbutolol, Labetalol, Pindolol, Metoprolol, Nadolol, Betaxolol, Bisoprolol, Timolol, or Propranolol
  - Calcium channel blockers: Nifedipine, Felodipine, Amlodipine, Diltiazem, or Verapamil

Ranolazine (Ranexa®) is denied when any of the following exclusion criteria are found:

- No documentation of a diagnosis of chronic angina
- No documentation of trial and failure with at least one medication from any of the following drugs
Long-acting nitrates: Isosorbide dinitrate, Isosorbide mononitrate, Nitroglycerin patches
Beta-blockers: Atenolol, Acebutolol, Carvedilol, Penbutolol, Labetalol, Pindolol, Metoprolol, Nadolol, Betaxolol, Bisoprolol, Timolol, or Propranolol
Calcium channel blockers: Nifedipine, Felodipine, Amlodipine, Diltiazem, or Verapamil

### Policy List of Applicable Drugs

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ranexa</td>
<td>ranolazine</td>
</tr>
</tbody>
</table>

### Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

### Policy References


### Policy Link to Related Policies

Printed 09/01/2009 10:38:55